

14 March 2023

Treatment of renal cell carcinoma and melanoma

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:

- Avelumab + Axitinib : 6
- Axitinib : <5
- Cabozantinib : 19
- Everolimus : <5
- Lenvatinib + Everolimus : <5
- Nivolumab : 24
- Nivolumab + Cabozantinib : 13
- Nivolumab + Ipilimumab : <5
- Pazopanib : <5
- Pembrolizumab + Axitinib : <5
- Pembrolizumab + Lenvatinib : <5
- Pembrolizumab monotherapy : <5
- Radiotherapy only : 9
- Sunitinib : <5
- Temsirolimus : <5
- Tivozanib : 22
- Other active systemic anti-cancer therapy : <5
- Palliative care only : Not available via RISOH

Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

- Cobimetinib : <5
- Dabrafenib : <5
- Dabrafenib AND Trametinib : 20
- Dacarbazine : <5
- Encorafenib AND Binimetinib : 28
- Ipilimumab : <5
- Ipilimumab AND Nivolumab : 8
- Nivolumab : 13
- Pembrolizumab : 54
- Trametinib : <5
- Vemurafenib : <5
- Vemurafenib AND Cobimetinib : <5
- Other active systemic anti-cancer therapy : Tebentafusp Map : <5
- Palliative care only : Not available via RISOH

14 March 2023

Q3. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Response: 40

Please note:

- Information as available from RISOH (regional information system Oncology/Haematology) Nov – Jan 2023
- Radiotherapy information supplied, then checked on RISOH to confirm Radiotherapy only
- Q3 OPCS data supplied by BHSCT information Activity stats
- Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.